Related references
Note: Only part of the references are listed.Identification of a β1/β2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening
Philipp Beck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Selective Inhibition of the Immunoproteasome by Ligand-Induced Crosslinking of the Active Site
Christian Dubiella et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening
Vinod Kasam et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Subunit specific inhibitors of proteasomes and their potential for immunomodulation
Alexei F. Kisselev et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2014)
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
Denise Niewerth et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
Gerjan de Bruin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome
Hao Fan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Computational Methods in Drug Discovery
Gregory Sliwoski et al.
PHARMACOLOGICAL REVIEWS (2014)
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Eva Maria Huber et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Drug discovery for a new generation of covalent drugs
Amit S. Kalgutkar et al.
EXPERT OPINION ON DRUG DISCOVERY (2012)
Molecular and Cellular Characterization of the Biological Effects of Ruthenium(II) Complexes Incorporating 2-Pyridyl-2-pyrimidine-4-carboxylic Acid
Vanessa Pierroz et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
Michael Basler et al.
JOURNAL OF IMMUNOLOGY (2010)
The 26S proteasome: assembly and function of a destructive machine
Nerea Gallastegui et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Regulation of CD8+ T cell development by thymus-specific proteasomes
Shigeo Murata et al.
SCIENCE (2007)
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
A. L. Goldberg
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Interferon-γ inducible exchanges of 20S proteasome active site subunits:: Why?
M Groettrup et al.
BIOCHIMIE (2001)
Share Paper
